Key Developments: CareFusion Corp (CFN)
34.13USD
21 May 2013
$0.03 (+0.09%)
$34.36
$34.13
$34.35
$34.08
1,355,181
1,722,166
$35.61
$23.77
Latest Key Developments (Source: Significant Developments)
Carefusion Corp Lowers FY 2013 Revenue Guidance; Reiterates FY 2013 EPS Guidance
Carefusion Corp announced that for fiscal 2013, it expects revenue to be flat to down low-single-digits on a percentage basis compared to fiscal 2012 revenue of $3.6 billion. The Company previously expected revenue to grow 1 to 3% on a constant currency basis. The Company reiterated its fiscal 2013 guidance range for adjusted diluted earnings per share (EPS) from continuing operations of $2.11 to $2.21. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $3.7 billion, EPS of $2.15 for fiscal 2013. Full Article
Carefusion Corp Announces Proposed Offering Of $300 Million Senior Notes
Carefusion Corp announced a private offering of $300 million aggregate principal amount of senior notes, the net proceeds of which the Company intends to use for general corporate purposes. Full Article
Carefusion Corp Reaffirms FY 2013 Guidance
Carefusion Corp announced that for fiscal 2013, it continues to expect consolidated revenue to grow 1% to 3% on a constant currency basis compared to fiscal 2012 revenue of $3.6 billion, adjusted diluted EPS from continuing operations to be in the range of $2.11 to $2.21. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $2.15 for fiscal 2013. Full Article
Carefusion Corp To Acquire Brazilian Respiratory Company Intermed
Carefusion Corp announced an agreement to acquire Intermed Equipamento Medico Hospitalar Ltda, a privately held, respiratory technologies company based in Sao Paulo, Brazil. Financial terms of the agreement were not disclosed. Full Article
Carefusion Corp Reaffirms FY 2013 Guidance
Carefusion Corp reaffirmed the fiscal 2013 guidance it provided on August 9, 2013 and does not believe the matter will have a meaningful impact on expected revenue, earnings or cash flow. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report EPS of $2.13 for fiscal 2013. Full Article
FDA Recalls Carefusion Corp's Infusion Pump-Reuters
Reuters reported that U.S. health regulators announced a recall of CareFusion's Alaris pump module Model 8100, saying a potential keypad malfunction in the infusion pump could cause serious injury or death. The U.S. Food and Drug Administration said the affected pump modules, used for delivering a variety of fluids, drugs and blood products to patients, were manufactured between October 2011 and February 2012. Full Article
Carefusion Corp Issues FY 2013 Guidance
Carefusion Corp announced that for fiscal 2013, it revenue to grow 1% to 3% on a constant currency basis compared to fiscal 2012 revenue of $3.6 billion. Adjusted diluted earnings per share from continuing operations are expected to be in the range of $1.92 to $2.02. Excluding acquisition-related amortization, adjusted diluted earnings per share from continuing operations are expected to be in the range of $2.11 to $2.21, compared to fiscal 2012 results of $2.00. Full Article
Carefusion Corp Recalls Infant Breathing Product-Reuters
Reuters reported that Carefusion Corp said it has recalled its AirLife Infant Breathing Circuit products because they could develop cracks during use, causing a leak in the closed ventilation system. About 280,000 of the disposable products being recalled were manufactured between June 1, 2010, and February 3, 2012, a CareFusion spokeswoman said. There have been no reports of patient harm associated with the products, Carefusion said. CareFusion has since improved its manufacturing process and is making a stronger component for its new breathing circuit products, which attach to a mechanical ventilator, the spokeswoman said. Carefusion notified hospitals in late May that it was removing the AirLife products from the market and advised them to destroy whatever remained in their inventory. The U.S. Food and Drug Administration classified the action as a Class I recall on its website on June 29, meaning the defective units could cause serious harm to a patient's health. Since May, nearly half of affected customers and distributors have either destroyed the items or reported they no longer have them, CareFusion said. Full Article
Natus Medical, Inc. Completes Acquisition Of Nicolet Neurodiagnostic Business From CareFusion Corp
Natus Medical, Inc. announced that it has completed the acquisition of the Nicolet neurodiagnostic business from CareFusion Corp that was announced on April 23, 2012. Natus funded the approximate $58 million cash purchase price with existing cash and borrowings under its credit facility. Full Article
Carefusion Corp Announces Acquisition Of U.K. Medical Limited
Carefusion Corp announced the acquisition of U.K. Medical Limited, a distributor of medical products to the National Health Service (NHS) and private health care sector in the United Kingdom. Terms of the deal were not disclosed. The acquisition, the Company's fifth, is part of CareFusion's strategy to expand globally by investing to build scale, infrastructure and local capabilities in key markets. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
